BPX 701 - Bellicum Pharmaceuticals/Leiden university Medical Center

Drug Profile

BPX 701 - Bellicum Pharmaceuticals/Leiden university Medical Center

Alternative Names: BPX701

Latest Information Update: 10 Aug 2016

Price : $50

At a glance

  • Originator Leiden University Medical Center
  • Developer Bellicum Pharmaceuticals; Leiden University Medical Center
  • Class Antineoplastics; Immunotherapies; T lymphocyte cell therapies
  • Mechanism of Action Immunostimulants; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Acute myeloid leukaemia; Malignant melanoma; Myelodysplastic syndromes; Neuroblastoma; Sarcoma; Uveal melanoma

Most Recent Events

  • 08 Aug 2016 US FDA approves IND application for BPX 701 in Acute myeloid lukaemia and Myelodysplastic Syndrome
  • 02 Jun 2016 Bellicum Pharmaceuticals plans phase I/II trials for Acute myeloid leukaemia (Refractory disease) and Myelodysplastic syndrome (IV)
  • 15 Mar 2016 Preclinical trials in Acute myeloid leukaemia in USA (IV) before March 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top